The company "Valartin Pharma" became a partner of the international scientific and practical conference "SOUU-2025. Achievements and prospects in diagnostics and treatment of diseases of the urinary system", which took place on April 11-12, 2025 in Kyiv (Mercure Congress Hall, conference hall "Spilberg", Vadym Getmana St., 6).

The conference was organized by the Union of Urological Oncologists of Ukraine (URUU), the National Cancer Institute, and the Center for Modern Urology.

The conference program included speeches by top speakers on the most relevant topics in oncology and urology. The most famous urology specialists and doctors from other countries took part in one event. The conference presented the leading urological schools of Ukraine - the cities of Kyiv, Dnipro, Kryvyi Rih, Kharkiv, Odessa, Lviv, Poltava, Uzhgorod, Vinnytsia, Ternopil.

The conference discussed issues of plastic and reconstructive urology and oncourology, minimally invasive technologies in urology, urogynecology, pelvic floor tumors, urinary tract infections, neurogenic urology (stress incontinence, hyperreflexic bladder).

In his report "Restoration of sexual function after surgical treatment of benign prostatic obstruction", Professor, Doctor of Medical Sciences, Chief Researcher of the Department of Sexopathology and Andrology of the State Institution "Institute of Urology named after Acad. O.F. Vozianov NAMS of Ukraine" Yuriy Mykolayovych Gurzhenko drew attention to the relevance of the use of the drug VALARGIN PLUS in the complex therapy of erectile dysfunction.

Particular attention was paid to the drug therapy of erectile dysfunction, where among the various groups of drugs, precursors of nitric oxide (VALARGIN PLUS) occupy a significant place.

VALARGIN PLUS is an additional source of amino acids L-arginine and L-citrulline, which are involved in protein synthesis in the human body and contribute to the normalization of the work of all organs and systems.

A combination of amino acids L-arginine and L-citrulline in the optimal dosage:

• to restore erectile function due to a rapid increase in the level of nitric oxide, which leads to relaxation of the smooth muscles of the cavernous tissue and an increase in blood flow to achieve an erection

The report presented the results of prescribing VALARGIN PLUS on the basis of the speaker's medical institution.

The results of the drug's use are as follows:

• the use of VALARGIN PLUS as monotherapy allows improving erectile function in 96% of patients;
• VALARGIN PLUS improves nocturnal erections in both men with erectile dysfunction after surgery and in healthy men.